{
 "PrintNo":"S5421","Session":2025,"Chamber":"SENATE","BillType":"Senate","Published":"2025-02-21T11:27:34.180392Z",
 "Status":"IN_SENATE_COMM","Committee":"Health",
 "Milestones":[{"Type":"IN_SENATE_COMM","Date":"2025-02-21","Committee":"Health"}],
 "Actions":[{"Text":"REFERRED TO HEALTH","Date":"2025-02-21","Chamber":"SENATE"}],
 "Sponsors":[{"ID":1232,"Name":"James Skoufis","Short":"SKOUFIS"}],
 "Title":"Designates Xylazine as a schedule III depressant",
 "Summary":"Designates Xylazine as a schedule III depressant.","LawSection":"Public Health Law",
 "LawCode":"Amd ยง3306, Pub Health L",
 "ActClause":"AN ACT to amend the public health law, in relation to designating Xylazine as a schedule III depressant",
 "PreviousVersions":["S5439-2023"]
}